Beginning in January of 2024, the Commission on Dietetic Registration (CDR) bumped up the minimum required education level for prospective RDs from a bachelor’s degree to a master’s degree.1 It’s the ...

Annexon (NASDAQ:ANNX) used its presentation at the 44th Annual J.P. Morgan Healthcare Conference to outline a set of ...

Ocugen has announced the publication of positive results from its phase 1 GARDian1 trial of OCU410ST, a gene therapy for ...

Unifrance Boss Gilles Pélisson reflects on first mandate and lays out how animation and co-productions are driving the appeal ...

Randomized clinical trials remain the gold standard for establishing a medication's effects, producing the evidence by which ...

Meta Platforms has entered into partnerships with nuclear energy companies Oklo and Constellation Energy to secure long term ...

New online platform provides evidence-based protection guidance for families, schools, and businesses amid escalating digital dangers The cyber threats facing UK families, schools, and businesses in ...

– Single subcutaneous dose of ADX-038 achieved near-complete alternative pathway suppression for 6 months, supporting potent and selective CFB silencing – – Phase 2 studies are ongoing to assess the ...

FDA approval enables Complement Therapeutics to start the Opti-GAIN phase 1/2 trial for CTx001 in GA secondary to AMD. CTx001 is an AAV-based gene therapy delivering a truncated Complement Receptor 1 ...

Complement 3 glomerulopathy (C3G) is a rare kidney disease that affects your body’s innate immune system (complement system). Complement 3 glomerulopathy (C3G) is a kidney disease that’s caused by ...